Discussion about this post

User's avatar
Etienne Taylor's avatar

As someone who spent 13 years running a clinical trial repository of my own design, I’d about given up trying to catalogue the ways in which the ‘ethical pharmaceutical’ industry and Google have conspired to lead a disinterested press corps around by the nose. I greatly appreciate your work here.

Expand full comment
Dina Goldin, Ph.D.'s avatar

I was expecting to see a discussion of the 2nd reason for RCT preference, besides serving as barrier to entry. It's also easier to twiddle RCT design parameters to obtain desired goal -- either to boost one's own drug or to suppress another one. Is this discussed anywhere in the book?

Expand full comment
3 more comments...

No posts